Slime in lungs
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
The Role of Slime in Pulmonary Infections
Introduction to Slime in Lungs
Slime, or mucopolysaccharide, produced by certain bacteria, plays a significant role in the pathogenesis of pulmonary infections. This substance can interfere with the immune response, complicate treatment, and contribute to chronic infections, particularly in patients with conditions like cystic fibrosis (CF).
Pseudomonas aeruginosa and Slime Production
Impact on Neutrophil Function
Pseudomonas aeruginosa, a common pathogen in CF patients, produces a slime layer that affects neutrophil function. Studies have shown that the phagocytosis of P. aeruginosa by neutrophils is significantly less efficient compared to other bacteria like Staphylococcus aureus. This reduced efficiency is partly due to the slime layer, which acts as a barrier, hindering the interaction between neutrophils and the bacteria. Additionally, while opsonization can temporarily increase the uptake of P. aeruginosa, the effect diminishes over time, indicating the persistent challenge posed by the slime layer.
Antiphagocytic Properties
The slime layer of P. aeruginosa also exhibits antiphagocytic properties, which allow the bacteria to evade the normal clearance mechanisms of the lung. This evasion is primarily due to the barrier effect of the slime, which inhibits the phagocytic killing of bacteria by immune cells such as macrophages and polymorphonuclear leukocytes. This mechanism is crucial in the persistence and severity of chronic respiratory diseases like CF.
Slime in Medical Devices and ICU Settings
Microorganisms producing slime can adhere to the surfaces of medical devices, such as endotracheal tubes, complicating infections in intensive care unit (ICU) settings. However, studies have found no direct correlation between the bacteria on these devices and those responsible for pneumonia, suggesting that while slime presence is significant, other factors also contribute to infection development.
Biofilm Formation and Antibiotic Resistance
Biofilm vs. Planktonic Growth
P. aeruginosa often grows in a biofilm, or slime layer, in the airways of CF patients. This growth mode is different from the planktonic (free-floating) mode typically used in conventional antimicrobial susceptibility testing. Biofilm formation is associated with increased resistance to antibiotics, making infections harder to treat .
Antimicrobial Susceptibility Testing
Recent studies have compared the effectiveness of antibiotic therapies guided by biofilm antimicrobial susceptibility testing versus conventional methods. The findings suggest that while biofilm-based testing is safe, it does not significantly improve microbiological or clinical outcomes compared to conventional testing. This indicates that current evidence is insufficient to recommend biofilm-based testing over traditional methods for treating P. aeruginosa infections in CF patients .
Conclusion
The slime produced by bacteria like Pseudomonas aeruginosa plays a critical role in the pathogenesis of pulmonary infections, particularly in chronic conditions such as cystic fibrosis. It interferes with immune responses, complicates treatment, and contributes to the persistence of infections. While biofilm-based antimicrobial susceptibility testing offers a potential approach to addressing these challenges, current evidence does not support its superiority over conventional methods. Further research is needed to develop more effective treatment strategies that can overcome the protective barrier of bacterial slime.
Sources and full results
Most relevant research papers on this topic